House Speaker seeks probe on approval process of COVID-19 treatments
HOUSE Speaker Lord Allan Jay Q. Velasco has filed a resolution to probe the Department of Health (DoH) and the Food and Drug Administration (FDA) on the registration and distribution of medicines for coronavirus treatment. On Wednesday, the Speaker and Deputy Speaker Bernadette Herrera-Dy filed House Resolution No. 1711, which calls on the committee on good government and public accountability to investigate the two agencies on the approval process of coronavirus disease 2019 (COVID-19) treatments. Both lawmakers called the stringent guidelines of both agencies, specifically FDA Circular No 2020-12, as “arbitrary, bureaucratic, and inhumane for causing unnecessary delays in the approval and clearance of drugs and therapeutics for emergency use authorization or for use of drugs under compassionate special permit against the dreaded COVID-19 disease.” The DoH and FDA gave several warnings on the use of ivermectic for COVID-19 treatment since there are insufficient studies that show its effectiveness for that purpose. Ivermectin for veterinary use is the only locally registered product and FDA has warned against human intake. The House resolution came amid the push by some lawmakers, who are not medical practitioners, to approve the anti-parasitic drug ivermectin as a COVID-19 treatment. Ms. Herrera-Dy is among those solons and has said that she uses the drug as a prevention against COVID-19.